Orega Biotech

Executive Summary

Orega Biotech is a French biotechnology company founded in 2018, headquartered in the Lyon area, specializing in developing first-in-class monoclonal antibodies against novel immune checkpoints for cancer immunotherapy. The company's lead program, an anti-CD39 antibody, is partnered with Innate Pharma and AstraZeneca and has advanced into Phase 2 clinical trials. This partnership provides significant validation and resources, de-risking the development path. Orega Biotech leverages deep expertise in tumor immunology to target immunosuppressive mechanisms within the tumor microenvironment, aiming to restore anti-tumor immune responses. The company operates in the competitive immuno-oncology space but differentiates itself by focusing on undiscovered or under-explored checkpoints like CD39, which plays a key role in adenosine-mediated immunosuppression. With a lean structure and strategic collaborations, Orega is positioned to generate compelling clinical data in the near term while exploring additional pipeline candidates. Orega Biotech's strategy hinges on successful execution of its Phase 2 trial for the anti-CD39 antibody, with potential for proof-of-concept data that could support accelerated development or out-licensing. The company also benefits from the expertise and infrastructure of its larger partners, which may facilitate regulatory interactions and manufacturing. While still private and early-stage, Orega's focus on a validated target (CD39) with a clear biological rationale and strong partnership backing suggests a promising risk/reward profile. Key risks include competitive developments (other anti-CD39 programs) and typical clinical trial uncertainties. Overall, Orega represents a high-upside opportunity in the immuno-oncology space, contingent on positive Phase 2 results and continued partnership support.

Upcoming Catalysts (preview)

• H1 2027Phase 2 interim data readout for anti-CD39 antibody55% success
• H2 2026Expansion of partnership with AstraZeneca or new collaboration40% success
• 2027IND filing or preclinical data for next pipeline candidate30% success